Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. The company is headquartered in Melville, New York. The company went IPO on 2022-04-14. The firm is engaged in offering patented smart-safety syringe products to the healthcare industry. The firm's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. The company Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. The company also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The company has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.
최신 재무제표(Form-10K)에 따르면, John Hancock Income Securities Trust의 총 자산은 $0이며, 순손실입니다.
STSS의 주요 재무 비율은 무엇인가요?
John Hancock Income Securities Trust의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Sharps Technology Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
John Hancock Income Securities Trust 주요 수익원은 Overseas Art Study Services이며, 최신 수익 발표에서 수익은 33,862,339입니다. 지역별로는 China이 John Hancock Income Securities Trust의 주요 시장이며, 수익은 37,297,741입니다.
Sharps Technology Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 John Hancock Income Securities Trust의 순손실은 $0입니다.
Sharps Technology Inc에 부채가 있나요?
no, John Hancock Income Securities Trust의 부채는 0입니다.
Sharps Technology Inc의 발행 주식은 몇 주인가요?
John Hancock Income Securities Trust의 총 발행 주식은 0주입니다.